1Y Target$15.58Near-term target
5Y Target$21.82Compound horizon
10Y Target$32.08Long-dated conviction
FCF—TTM—FCF not applicable for this sector (bank / insurer / REIT) or data unavailable
Rev+77.7%TTM YoYARevenue +77.7% — hypergrowth, top decile
D/E0.01totalAD/E 0.01 — essentially debt-free, pristine balance sheet · Total D/E computed from balance sheet (short-term + long-term debt + lease obligations) ÷ stockholders equity. More accurate than native field, which often uses long-term debt only.
P/E11.1xA-P/E 11.1 — cheap relative to market and most sectors
PEG0.14proxyAPEG 0.14 — exceptional; paying well under fair value for growth · PEG proxy: P/E ÷ revenue growth % (true PEG requires forward EPS estimates, not in Finnhub free tier).
Why now
Banking · market cap $7.2b. 4% off the 52-week high of $14.12. Revenue growing +78% — in hypergrowth territory. PEG 0.14 — paying under fair value for the growth rate.
Moat
Net margin 31% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. Financial moat — scale of deposit base / underwriting franchise plus regulatory capital advantages. The largest players compound book value through cycles that erase smaller competitors.
Risk
Balance-sheet financial — book value, net interest margin, and credit loss provisions are the lever points; a rates regime change or a deterioration in the loan book moves the stock more than EPS does.
Horizon
1-3 yr $15.58 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $21.82 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $32.08 if current growth sustains into durable earnings power.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See
terms and
methodology for full disclosures.